Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Oruc Melds Life Sciences, Antitrust Focus (FTC Watch)

Related Content

Federal Court of Appeals Rejects HHS Stance on Section 340B Contract Pharmacies

Top 5 Compliance Issues for Medtech Firms Transitioning To Data-Enabled Solutions (MedCity News)

CMS Issues First Request for Public Comments on the Medicare Drug Price Negotiation Program “Small Biotech” Exception – Due March 27, 2023

In the Metaverse, Existing Healthcare Rules Apply

Implications of Abortion Laws for Fertility Services

USPTO Launches the Cancer Moonshot Expedited Examination Pilot Program

New Appropriations Bill Reforms Antitrust Laws and Modifies HSR Fees

Year in Review: Top Biosimilars-Related Regulatory Developments of 2022

Goodwin Continues Expansion in Philadelphia and New York with Four Life Sciences Partners

Goodwin Adds Four More Partners to Life Sciences Team (Bloomberg Law)

Former OIG Chief Counsel: Noncompliance in Complex Environment at Times Is ‘Inevitable’ (Report on Medicare Compliance)

A ‘Bellwether’ Year for Life Sciences: Lawyers Forecast M&A Uptick as Regs Remain Busy (Law.com)

The Inflation Reduction Act & Medicare Pricing for Drugs and Biologics

UK Biotech Financing Report 2022 (UK BioIndustry Association)

Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

Phila. Law Firm Leaders Find Opportunity, Not Threat, in Goodwin Arrival (Law.com)

Life Sciences

Medtech

Complex Litigation & Dispute Resolution

Antitrust & Competition

Antitrust Services for Life Sciences Companies

Litigation